Navigation Links
Myriad's Prolaris significantly modifies treatment decisions for prostate cancer patients
Date:1/29/2014

SALT LAKE CITY, Utah, Jan. 29, 2014 Myriad Genetics, Inc. (NASDAQ: MYGN) today announced results from PROCEDE 500, a clinical utility study with its Prolaris test, at the 2014 ASCO Genitourinary Cancers Symposium in San Francisco, Calif. The study demonstrated the significant clinical value of Prolaris to physicians who are treating men with prostate cancer. Prolaris is a prognostic test that accurately predicts prostate cancer-specific death and metastases and has been validated in 11 clinical studies with more than 5,000 patients.

"Prolaris has opened the door to a new era of personalized cancer treatment for men with prostate cancer," said Michael Brawer, M.D. vice president of medical affairs at Myriad Genetic Laboratories. "The Prolaris score is a stronger predictor of prostate cancer death and recurrence than either Gleason score or PSA (prostate specific antigen), and delivers clinically relevant information not provided by any other prognostic test."

PROCEDE 500 is an ongoing prospective registry study designed to examine the clinical utility of Prolaris. Currently, 331 patients have been enrolled and 150 clinicians have completed surveys in 305 cases to assess the influence of the Prolaris score on clinical decision making. Results for these interim data show that in 65 percent of cases, physicians changed their intended therapy and selected a different treatment based on the Prolaris test score. In 40 percent of patients, physicians reduced the therapeutic burden on patients and opted for conservative management options such as active surveillance and watchful waiting. In 25 percent of cases, physicians increased treatments including the use of surgery or radiation, and in 35 percent of cases, physicians did not change their treatment plans. Full results from PROCEDE 500 have been submitted to a peer-reviewed medical journal for publication.

"As a clinical researcher, I advocate for evidence-based medicine. The Prolaris test score accurately tells me if a patient has an aggressive prostate cancer or not and guides my treatment decisions," said Ashok Kar, M.D., St. Joseph's Hospital in Orange, Calif. "As a practicing physician, I must ask the same question for every patient; should I use surgery or radiation, or should I use active surveillance and watchful waiting? Prolaris helps me answer this critical clinical question."


'/>"/>

Contact: Ronald Rogers
rrogers@myriad.com
801-584-3065
Myriad Genetics, Inc.
Source:Eurekalert

Related biology news :

1. Targeted treatment can significantly reduce relapse in children with AML leukemia
2. Children are significantly more likely to develop PTSD if the mother is already afflicted
3. Amgen Presents Pooled Analysis Showing AMG 145 Significantly Reduced LDL Cholesterol In Over 1,200 Patients
4. Study shows probiotic Lactobacillus reuteri NCIMB 30242 significantly increased vitamin D levels
5. Synthetic biology research community grows significantly
6. Resistant starch content of potatoes varies significantly by preparation and service method
7. Ceramic indoor cookstove use did not significantly lower child pneumonia risk in rural Kenya
8. Chernobyl cleanup workers had significantly increased risk of leukemia
9. New study: Snacking on raisins significantly reduces overall post-meal blood sugar levels
10. Wistar scientists decipher structure of NatA, an enzyme complex that modifies most human proteins
11. Promising class of antibiotics discovered for treatment of drug-resistant tuberculosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/5/2017)... April 4, 2017 KEY FINDINGS ... expand at a CAGR of 25.76% during the forecast ... the primary factor for the growth of the stem ... https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The global stem cell ... application, and geography. The stem cell market of the ...
(Date:3/30/2017)... 2017 The research team of The Hong ... fingerprint identification by adopting ground breaking 3D fingerprint minutiae recovery and ... speed and accuracy for use in identification, crime investigation, immigration control, ... ... A research team led ...
(Date:3/27/2017)... ROCKVILLE CENTRE, N.Y. , March 27, 2017 ... by Healthcare Information and Management Systems Society (HIMSS) ... Analytics Outpatient EMR Adoption Model sm . In ... top 12% of U.S. hospitals using an electronic ... recognized CHS for its high level of EMR ...
Breaking Biology News(10 mins):
(Date:6/23/2017)... ... ... Biova, LLC., the leader in water soluble egg membrane ingredients, announced today ... bring a wealth of scientific experience in the food, beverage, nutrition and dietary supplement ... of four major global companies in the last 4 decades. He has a ...
(Date:6/23/2017)... and CARDIFF, UK (PRWEB) , ... June 23, 2017 , ... ... and Brian Lula, president of Physik Instrumente USA, have been selected as this year’s ... photonics . , The two have been invited along with other honorees to accept ...
(Date:6/23/2017)... (PRWEB) , ... June 23, 2017 , ... ... for model aircraft flying hobbyists, and the University Aviation Association (UAA), the unifying ... students. The UAS4STEM Collegiate Challenge will encourage teamwork, competition, and success through a ...
(Date:6/22/2017)... ... 21, 2017 , ... RMC Pharmaceutical Solutions, Inc. announces the ... to manage the new site. , Tim has 25 years of pharmaceutical experience, ... role as the Director of Manufacturing and Supplier Quality Assessment. This group ...
Breaking Biology Technology: